Management Team
- Previously Chief Operating Officer of SynthRx; Associate Director of Drug Development at Kemia, and Group Leader at Corvas International
- X01 grantee from NINDS for RHAPSODY Phase 2 study of 3K3A-APC in stroke patients
- Previously CMO at Catalyst Biosciences; Sr. Global Medical Program Director at CSL Bering, SVP & CMO at Inspiration Biopharmaceuticals, and Chief of Critical Care Medicine , University of New Mexico
- Former Clinical Research Physician and Medical Director, Acute Care, Eli Lilly and Company
- Headed post-marketing clinical trials and medical affairs for recombinant Activated Protein C (Xigris) in severe sepsis
• Senior Manager of the tax group, Pioneer Wealth Partners
• Formerly Senior Associate at the Quellos Group, providing wealth management services to high net worth families
• Certified Public Accountant
- Legal expertise in Corporate Finance, M&A, Insurance & Risk Management and IP
- Contracting including Licensing, Drug Manufacturing, Material Transfers and Clinical Trials
- Previously General Counsel to Zilkha Biomass Energy and General Counsel to Zilkha Renewable Energy
- Principal, LKH & Associates
- Previously Vice President, Regulatory Affairs and Clinical Operations, La Jolla Pharmaceutical Company
- Vice President, Clinical Operations and Regulatory Affairs for Light Sciences Oncology
• Principal Consultant, ProCon International: Independent technical regulatory and process development consultant in mainly the recombinant protein and synthetic peptide areas since 1990
• Previously Technical Director of BioTechnetics, and Manager, Technical & Scientific Services for Brunswick GmbH